{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:36:46Z","timestamp":1790807806844,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06446-6","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:40:05Z","timestamp":1778690405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-institutional external validation of the European risk classification for high-grade Ta non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Manon","family":"Courn\u00e8de","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Lottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Budowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Poyet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumiguie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Alvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Hendricksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Thenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Verhoest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"6446_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjurol.2025.103011","volume":"35","author":"M Roumigui\u00e9","year":"2025","unstructured":"Roumigui\u00e9 M, Xylinas E, Gabriel PE, Allory Y, Audenet F, Bajeot AS et al (2025) French recommendations of the AFU Oncology Committee for bladder cancer: update 2025. Fr J Urol 35:103011. https:\/\/doi.org\/10.1016\/j.fjurol.2025.103011","journal-title":"Fr J Urol"},{"key":"6446_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075942","volume":"13","author":"T Lebret","year":"2023","unstructured":"Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X et al (2023) Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open 13:e075942. https:\/\/doi.org\/10.1136\/bmjopen-2023-075942","journal-title":"BMJ Open"},{"key":"6446_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, Van Der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with Stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"key":"6446_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049","journal-title":"J Urol"},{"key":"6446_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.007","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, Soria F, Pradere B, Krajewski W, D\u2019Andrea D et al (2025) Oncological outcomes in Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.03.007","journal-title":"Eur Urol Oncol"},{"key":"6446_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M et al (2009) CUETO - predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182:2195\u20132203. https:\/\/doi.org\/10.1016\/j.juro.2009.07.016","journal-title":"J Urol"},{"key":"6446_CR7","doi-asserted-by":"publisher","first-page":"106.e1","DOI":"10.1016\/j.urolonc.2021.10.008","volume":"40","author":"Z Dovey","year":"2022","unstructured":"Dovey Z, Pfail J, Martini A, Steineck G, Dey L, Renstr\u00f6m L et al (2022) Bladder cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urol Oncol 40:106.e1-106.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2021.10.008","journal-title":"Urol Oncol"},{"key":"6446_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2013.372","volume":"109","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS et al (2013) 6 - Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 109:1460\u20131466. https:\/\/doi.org\/10.1038\/bjc.2013.372","journal-title":"Br J Cancer"},{"key":"6446_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al (2024) European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-a summary of the 2024 guidelines update. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027","journal-title":"Eur Urol"},{"key":"6446_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, Turturica D, Bauerov\u00e1 L, Bruins HM et al (2021) 2 - European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79:480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"key":"6446_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","volume":"4","author":"BWG Van Rhijn","year":"2021","unstructured":"Van Rhijn BWG, Hentschel AE, Br\u00fcndl J, Comp\u00e9rat EM, Hern\u00e1ndez V, \u010capoun O et al (2021) 11 - Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non\u2013muscle-invasive bladder cancer: a multicenter European Association of Urology non\u2013muscle-invasive bladder cancer guidelines panel study. Eur Urol Oncol 4:182\u2013191. https:\/\/doi.org\/10.1016\/j.euo.2020.12.002","journal-title":"Eur Urol Oncol"},{"key":"6446_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.01.005","volume":"76","author":"SR Williamson","year":"2010","unstructured":"Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L (2010) Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 76:112\u2013126. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.01.005","journal-title":"Crit Rev Oncol Hematol"},{"key":"6446_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.eursup.2010.08.005","volume":"9","author":"D Lamm","year":"2010","unstructured":"Lamm D, Persad R, Colombel M, Brausi M (2010) Maintenance Bacillus Calmette-Gu\u00e9rin: the standard of care for the prophylaxis and management of intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol Suppl 9:715\u2013734. https:\/\/doi.org\/10.1016\/j.eursup.2010.08.005","journal-title":"Eur Urol Suppl"},{"key":"6446_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16780","author":"M Longoni","year":"2025","unstructured":"Longoni M, Scilipoti P, De Angelis M, Zaurito P, Tremolada G, Santangelo A et al (2025) Contemporary outcomes in non\u2010muscle\u2010invasive bladder cancer: a large European multicentre study. BJU Int. https:\/\/doi.org\/10.1111\/bju.16780","journal-title":"BJU Int"},{"key":"6446_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/cncr.33300","volume":"127","author":"T Garg","year":"2021","unstructured":"Garg T, McMullen CK, Leo MC, O\u2019Keeffe\u2010Rosetti MC, Weinmann S, Nielsen ME (2021) Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle\u2010invasive bladder cancer in a multisite, community\u2010based cohort. Cancer 127:520\u2013527. https:\/\/doi.org\/10.1002\/cncr.33300","journal-title":"Cancer"},{"key":"6446_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2023.01.004","volume":"6","author":"IJ Beijert","year":"2023","unstructured":"Beijert IJ, Hentschel AE, Br\u00fcndl J, Comp\u00e9rat EM, Plass K, Rodr\u00edguez O et al (2023) 1 - Prognosis of primary papillary Ta grade 3 bladder cancer in the non-muscle-invasive spectrum. Eur Urol Oncol 6:214\u2013221. https:\/\/doi.org\/10.1016\/j.euo.2023.01.004","journal-title":"Eur Urol Oncol"},{"key":"6446_CR17","doi-asserted-by":"publisher","first-page":"491.e11","DOI":"10.1016\/j.urolonc.2022.06.008","volume":"40","author":"W Krajewski","year":"2022","unstructured":"Krajewski W, Aumatell J, Subiela JD, Nowak \u0141, Tukiendorf A, Moschini M et al (2022) <article-title update=\"added\">Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high\u2013grade non-muscle-invasive urothelial bladder cancer. Urol Oncol 40:491.e11-491.e19. https:\/\/doi.org\/10.1016\/j.urolonc.2022.06.008","journal-title":"Urol Oncol"},{"issue":"5S","key":"6446_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001109788.99555.df.01","volume":"213","author":"JCC Kwong","year":"2025","unstructured":"Kwong JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Ringa M et al (2025) Should primary, solitary, and small (<3 cm) TaHG tumors be classified as intermediate- or high-risk disease\u202f? A retrospective, international cohort study. J Urol 213(5S):e241. https:\/\/doi.org\/10.1097\/01.JU.0001109788.99555.df.01","journal-title":"J Urol"},{"key":"6446_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/bco2.363","volume":"5","author":"T Ajami","year":"2024","unstructured":"Ajami T, Han S, Blachman-Braun R, Hougen HY, Avda Y, Gonzalgo ML et al (2024) Optimal management for primary high grade Ta bladder cancer: role of re-staging TURBT and intravesical adjuvant therapy. BJUI Compass 5:913\u2013919. https:\/\/doi.org\/10.1002\/bco2.363","journal-title":"BJUI Compass"},{"key":"6446_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00345-025-05613-5","volume":"43","author":"A Eraky","year":"2025","unstructured":"Eraky A, Hug B, Ben-David R, Kolanukuduru KP, Waingankar N, Attalla K et al (2025) Efficacy of Bacillus Calmette-Gu\u00e9rin compared to sequential gemcitabine and docetaxel in Ta high-grade non-muscle invasive bladder cancer. World J Urol 43:255. https:\/\/doi.org\/10.1007\/s00345-025-05613-5","journal-title":"World J Urol"},{"key":"6446_CR21","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.euo.2025.06.003","volume":"8","author":"P-E Gabriel","year":"2025","unstructured":"Gabriel P-E, Roumigui\u00e9 M, Marcq G, Allory Y, Audenet F, Bajeot AS et al (2025) The evolving landscape of systemic immunotherapy for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non-muscle-invasive bladder cancer: at the edge of a tsunami? Eur Urol Oncol 8:1174\u20131181. https:\/\/doi.org\/10.1016\/j.euo.2025.06.003","journal-title":"Eur Urol Oncol"},{"key":"6446_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.017","author":"M Roupret","year":"2025","unstructured":"Roupret M, Bertaut A, Pignot G, Neuzillet Y, Houede N, Mathieu R et al (2025) ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017","journal-title":"Ann Oncol"},{"key":"6446_CR23","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH et al (2025) Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31:2806\u20132814. https:\/\/doi.org\/10.1038\/s41591-025-03738-z","journal-title":"Nat Med"},{"key":"6446_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis M, Palou Redorta J, Nishiyama H, Krawczy\u0144ski M, Seyitkuliev A, Novikov A et al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. The Lancet 406:2221\u20132234. https:\/\/doi.org\/10.1016\/S0140-6736(25)01897-5","journal-title":"The Lancet"},{"key":"6446_CR25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-17-2719","volume":"24","author":"KEM Van Kessel","year":"2018","unstructured":"Van Kessel KEM, Van Der Keur KA, Dyrskj\u00f8t L, Algaba F, Welvaart NYC, Beukers W et al (2018) Molecular markers increase precision of the European Association of Urology Non\u2013Muscle-Invasive Bladder Cancer Progression Risk Groups. Clin Cancer Res 24:1586\u20131593. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2719","journal-title":"Clin Cancer Res"},{"key":"6446_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.euo.2024.12.010","volume":"8","author":"G Mjaess","year":"2025","unstructured":"Mjaess G, Diamand R, Roumegu\u00e8re T (2025) The fallacy of categorization in urology: a call for continuous thinking in the era of artificial intelligence. Eur Urol Oncol 8:239\u2013241. https:\/\/doi.org\/10.1016\/j.euo.2024.12.010","journal-title":"Eur Urol Oncol"},{"key":"6446_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2025.05.035","volume":"88","author":"SS Chang","year":"2025","unstructured":"Chang SS, Launer B, Narayan V, Patil D, O\u2019Donnell MA, Hensley PJ et al (2025) Computational Histology Artificial Intelligence (CHAI) enhances risk stratification of high-grade Ta non\u2013muscle-invasive bladder cancer in a multicenter cohort: comparison to current European Association of Urology and American Urological Association stratification schemes. Eur Urol 88:411\u2013413. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.035","journal-title":"Eur Urol"},{"key":"6446_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2026.01.005","author":"P-E Gabriel","year":"2026","unstructured":"Gabriel P-E, Xylinas E (2026) The future of non-muscle-invasive bladder cancer: towards a molecular-digital paradigm for personalized management. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2026.01.005","journal-title":"Eur Urol Focus"},{"key":"6446_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup V, \u010capoun O, Cohen D, Hern\u00e1ndez V, Babjuk M, Burger M et al (2017) Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization grading classification systems in non\u2013muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel systematic review. Eur Urol 72:801\u2013813. https:\/\/doi.org\/10.1016\/j.eururo.2017.04.015","journal-title":"Eur Urol"},{"key":"6446_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/cncr.26402","volume":"118","author":"K Chamie","year":"2012","unstructured":"Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR et al (2012) Quality of care in patients with bladder cancer: a case report? Cancer 118:1412\u20131421. https:\/\/doi.org\/10.1002\/cncr.26402","journal-title":"Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06446-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06446-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:40:05Z","timestamp":1778690405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06446-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6446"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06446-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this study, oral consent was obtained for every patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"358"}}